drugset / Trial / NCT03317457
Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of the trial is to assess the efficacy of Durvalumab and Tremelimumab in comparison to doxorubicin in treatment-naïve Soft tissue sarcoma patients
Timeline
- Start
- 2017-12-15
- Primary completion
- 2022-08-12
- Completion
- 2022-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxorubicin | Other / unclassified | 75 mg/m2 | — |
| Subject | Durvalumab | Monoclonal antibody | 1.5 g | — |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | — |